Concert Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Concert Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
564,137
2.41%
59,546
0%
07/31/2018
iShares Russell 2000 ETF
445,743
1.9%
-237
0.01%
09/06/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
369,500
1.58%
0
0.25%
06/30/2018
TIAA-CREF Small Cap Equity Fund
295,700
1.26%
0
0.12%
05/31/2018
iShares Nasdaq Biotechnology ETF
268,045
1.14%
-3,507
0.04%
09/06/2018
Franklin Biotechnology Discovery Fund
207,400
0.89%
0
0.22%
03/31/2018
iShares Russell 2000 Value ETF
198,231
0.85%
0
0.03%
09/06/2018
Vanguard Extended Market Index Fund
193,108
0.83%
101
0%
07/31/2018
Northern Small Cap Value Fund
190,175
0.81%
93,075
0.08%
03/31/2018
DFA US Small Cap Portfolio
187,569
0.8%
67,549
0.01%
04/30/2018
| Address |
99 Hayden Avenue
Lexington Massachusetts 02421
United States
|
|
Employees
|
- |
| Website |
http://www.concertpharma.com |
| Updated |
07/08/2019 |
| Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. |
